Despite the existence of ocular immune privilege, immune rejection may be a barrier to successful retinal transplantation. We have examined in mice the extent to which the subretinal space (SRS) is an immune privileged site, and whether retinal pigment epithelium and neuronal retinal tissue have properties of immune privileged tissues. We report that (1) The SRS is an immune privileged site; (2) Neonatal RPE is an immune privileged tissue; (3) Neuronal retina is a partially immune privileged tissue; and (4) Microglia within neonatal neural retina grafts promote photoreceptor differentiation, become activated, and induce sensitization of the recipient and serve as targets of immune rejection. Ó
Introduction
An unfortunately large number of diseases that affect the retina destroy its neuronal elements. Since these cells are unable to regenerate in mammals, partial to complete permanent blindness is the outcome. Among clinicians, patients and their loved ones, hope for alleviation of retinal blindness lies in the realm of transplantation. On the one hand, experience gained in other fields of medicine has given rise to these optimistic expectations because clinical transplantation of solid organs ranging from kidney to heart is quite successful. In fact, corneal transplantation is not only the most frequently performed solid organ transplant in the western world, but it is the most successful. On the other hand, retinal transplantation resembles brain transplantation in offering formidable barriers to success. Connection of newly implanted neurons to existing elements and pathways of the central nervous system has yet to be attained experimentally with a level of reproducibility that gives confidence. Moreover, despite claims for immune privilege in the eye and the brain--which should promote the success of allografts of neural tissue--there is surprisingly little trustworthy information available about the immunobiology of retinal transplantation. The purpose of this review is to summarize experiments, chiefly conducted in our laboratory over the past 12 years that have yielded results that bear on the immunology and vulnerability to immune rejection of retinal grafts.
Principles of transplantation immunology
The rules of transplantation immunology were largely worked out in a brilliant series of experiments conducted by Sir Peter Medawar and his various colleagues during the 1940s and 1950s (Medawar, 1945) . Based largely on studies using skin grafts as a model system in laboratory animals (chiefly rodents), the principles deduced by Medawar have stood the test of time, and have been extended to embrace most other solid tissue transplants. Three basic principles appear to operate:
(1) Foreign tissue grafts display molecules (called transplantation or histocompatibility antigens) that are not present in the recipient. Grafts prepared from one member of a species and placed on a genetically different member of the same species are said to be ''allogeneic'' (allografts), whereas grafts prepared from a member of a species that is genetically identical to the recipient are Vision Research 42 (2002) [487] [488] [489] [490] [491] [492] [493] [494] [495] www.elsevier.com/locate/visres said to be ''syngeneic''. Grafts from donors of a different species are called ''xenogeneic'' (xenografts).
(2) Recipient T and B lymphocytes express surface receptors for antigen that recognize transplantation antigens on allografts or xenografts. Upon recognition, these lymphocytes become activated, clonally expand, and differentiate into a spectrum of specific immune effector modalities--T cells that mediate delayed hypersensitivity (DH), cytotoxic T cells, and a variety of functionally diverse antibodies. Almost invariably the initial recognition event occurs in secondary lymphoid organs (lymph nodes, spleen) that receive lymph/blood drainage from the site of engraftment. Since the drainage fluid contains antigenic information of the graft, T and B cell proliferation and differentiation take place in these secondary lymphoid organs. Once generated, graft-specific effector cells and molecules disseminate through the recipient's blood vasculature where they can be delivered to tissue sites.
(3) Donor-specific T cells and antibodies are carried via the blood vasculature to the site of engraftment where they leave the blood, migrate into the graft and its bed to recognize donor alloantigens again. This second episode of recognition initiates a destructive inflammatory process that eventuates in rejection. Non-specific host defense mechanisms, often referred to as the molecular and cellular mediators of innate immunity, are the most important proximate agents in procuring graft rejection.
Impact of immune privilege on transplantation
As Medawar was studying the immunologic basis of transplant rejection, he discovered the phenomenon of immunologic privilege (Medawar, 1948) , a term he coined to identify the experimental situation where an allograft of tissue placed in specialized sites in the body proved to be resistant to immune rejection. He determined that the anterior chamber of the eye and the brain had the properties of immune privileged sites. In the ensuing years, numerous other sites in the body have been found to be immune privileged sites (Barker & Billingham, 1977; Streilein, 1999) . These sites include the vitreous cavity within the eye, the gonads (testis and ovary), the adrenal cortex, and the maternal-fetal interface during pregnancy.
Similarly, other investigators have learned that certain organs and tissues of the body when implanted as allografts in conventional (non-immune privileged) sites enjoy prolonged, even indefinite, survival (Billingham & Boswell, 1953) . These tissues include the cornea, the liver, and the testis, tissues now called immune privileged tissues.
As one contemplates retinal transplantation, the issue of immune privilege becomes extremely important. The neural retina and the retinal pigment epithelium (RPE) are derived from neurectoderm and, like the brain, these tissues may display the inherent properties of immune privilege. The subretinal space (SRS), protected behind the blood:tissue barriers of the RPE (outer blood:retinal barrier) and the retinal microvasculature (inner blood: retinal barrier), may behave as an immune privileged site. The extent to which neural retina and RPE are immune privileged tissues, and the extent to which the SRS acts as an immune privileged site are important to know, since immune privilege might work to the advantage of retinal transplantation by inhibiting immune rejection of transplants.
Immunobiologic issues concerning transplants of neuronal retina and retinal pigment epithelium
Since 1989, our laboratory, led first by Dr. Luke Qi Jiang, has conducted a systematic series of studies into the immunobiology of retinal and pigment epithelial transplants, and has begun to probe into the presence and importance of immune privilege to the success of these transplants. The questions we have addressed from the basis of this communication:
(1) ''What are the respective fates of neuronal retina and pigment epithelium allografts in the SRS?'' The answer that the clinician wants ultimately to know is whether allografts of retinal tissue can survive--in an immunologic sense--in the SRS. Exploring this important in a murine model system helps to reveal the possible outcomes.
(2) ''Is the SRS an immune privileged site?'' It is reasonable to expect that when retinal transplantation is performed, the graft tissue will be inserted into the subretinal space. Whether this space possesses inherent immune privilege is likely to be important in determining whether the graft will succeed or not.
(3) ''Are neuronal retina and pigment epithelium able to function as immune privileged tissues?'' By implanting allografts in a non-immune privileged site--such as beneath the kidney capsule of the kidney--one can determine the extent to which the graft is able to avoid sensitizing its recipients and/or able to avoid destruction by already formed graft-specific effector modalities.
(4) ''Do cells of the retina (neurons, glia) and the RPE express transplantation antigens?'' For antigens encoded by the major histocompatibility complex (MHC), this question can be addressed directly by using antibodies specific for the various MHC-encoded alloantigens. For other transplantation antigens, indirect measures must be used since the molecular identity of these antigens has yet to be revealed. These indirect measures include detection of DH to donor-specific alloantigens in recipients of retinal transplants.
(5) ''Do allografts of neuronal retina and pigment epithelium sensitize their recipients?'' While there are a variety of assays that can detect whether a recipient has been sensitized by graft-derived antigens, our laboratory has relied chiefly on determining whether the recipient has acquired donor-specific DH.
(6) ''Are allografts of neuronal retina and pigment epithelium vulnerable to rejection?'' The fate of allografts can be compared with the fate of similar grafts obtained from donors genetically identical to the recipient. In this manner, the differential influences of allograft immunity (for allografts) and neurobiological considerations (for syngeneic grafts) can be distinguished.
Experimental results that bear on each of these questions are summarized in the following sections of this communication.
5.
What are the fates of neuronal retina and pigment epithelium grafts in the anterior chamber and subretinal space of the eye?
Our research efforts have been directed exclusively to studies conducted in inbred strains of mice. The high level of genetic and immunologic information that is available in this species more than compensates for the stringent technological barriers created by the small size of the mouse eye. In general, we have harvested neuronal retinal and pigment epithelium from neonatal mice (less than 24 h after birth). In most of the experiments to be described in this communication, the graft donors were pigmented C57BL/6 mice, and the recipients were albino BALB/c mice. These strains of mice possess completely different genes at the murine MHC, H-2, and these mouse strains also differ at a vast array of minor histocompatibility genes. Orthotopic skin grafts exchanged between these mouse strains are rejected acutely, i.e. between 8 and 11 days.
Jiang and his collaborators gathered considerable information concerning the fate of C57BL/6 neonatal neuronal retina (NNR) grafts that were implanted into the anterior chamber of eyes of BALB/c mice (Jiang & Streilein, 1991; Jiang, Jorquera, & Streilein, 1993) . These grafts flourished in this site, acquiring numerous, wellformed rosettes comprised of circumferentially disposed photoreceptors with outer segments pointing into the center. NNR grafts also developed recognizable layers of upper level retinal neurons, including ganglion cells. At 12 days post-implantation (p.i.) allogeneic and syngeneic NNR grafts were healthy, uninflamed, and indistinguishable from each other. Ear pinnae challenge at this time point of graft-bearing recipients with C57BL/6 alloantigenic cells failed to elicit DH. In fact, these mice had acquired donor-specific anterior chamber associated immune deviation (ACAID), a deviant form of systemic immunity that typically follows introduction of antigen into the anterior chamber Streilein, Ksander, & Taylor, 1997) . The absence of inflammation in these anterior chamber grafts, combined with the acquisition of donor-specific ACAID strongly suggest that immune privilege--a physiologic feature of the normal anterior chamber--had been extended to these grafts. Similarly, neonatal RPE obtained from C57BL/6 donors also established a healthy appearance in the anterior chamber of BALB/c mice, re-enforcing the idea that sustained graft acceptance might be due to immune privilege (Jiang, Jorquera, & Streilein, 1994) . Moreover, mice bearing allogeneic RPE in the anterior chamber displayed ACAID when ear-challenged with donor spleen cells on day 12 p.i.
Ear challenge with donor lymphoid cells is an immunizing maneuver in its own right. Therefore, it was anticipated that survival of NNR and RPE allografts in the anterior chamber following ear pinna challenge with donor lymphoid cells might be curtailed--and it was. A brisk inflammatory reaction appeared in eyes containing allogeneic RPE cells and these grafts were completely destroyed within 7 days of ear challenge. NNR allografts in the anterior chamber also began to deteriorate after ear challenge, but it took several weeks before the grafts were completely eliminated. It was of interest that the deterioration of these grafts was accompanied by little clinical or histologic evidence of inflammation (Jiang, Jorquera, Streilein, & Ishioka, 1995) .
These experiments have now been extended to include analysis of NNR allografts placed in the SRS of BALB/c mice. The fate of these grafts was virtually identical to that of grafts placed in the anterior chamber, suggesting that sustained survival was related to ''immune privilege''.
While much has been learned to date from these studies, they are not complete. Technical difficulties have prevented us so far from studying the fate of RPE grafts in the SRS, primarily because it has not yet been possible to devise a strategy that permits delivery of an intact sheet of RPE into this space.
Based on the results to date we are in a position to make several summary statements:
1. Both NNR and neonatal RPE allografts experience extended survival in the anterior chamber, suggesting that immune privilege is operative. 2. NNR allografts placed in the SRS display prolonged survival.
Is the subretinal space an immune privileged site?
The SRS is a potential space that separates the tips of the outer segments of the photoreceptors from the apical surface of the RPE. Retinal detachments that occur spontaneously or are induced experimentally by injections placed in the SRS render this potential space apparent. Events important to phototransduction and vision take place in this place, including the shuttling of oxidized and reduced retinal between photoreceptors and RPE with the aid of interphotoreceptor retinol binding protein. While this molecule is the primary component of the inter photoreceptor matrix, other molecules undoubtedly exist since RPE constitutively secrete growth factors, including transforming growth factor-beta, from their apical surfaces.
Jiang reported that transplants of allogeneic NNR placed in the SRS of mouse eyes enjoy prolonged survival. Taken at face value this suggests that immune privilege exists in the SRS, but since it was not known whether NNR itself is an immune privileged tissue, this result was less informative than originally thought. To address this issue without this risking this confusion, Wenkel recently injected allogeneic tumor cells (P815) into the SRS of eyes of adult BALB/c mice (Wenkel & Streilein, 1998) . When controls injections were placed subcutaneously, P815 cells were promptly destroyed by immune rejection. However, when injected into the SRS, P815 formed progressively growing tumors that were clinically and histologically detectable at 12 days. This result, which is similar to the findings after injection of P815 cells into the anterior chamber , provides direct evidence of the existence of immune privilege in the SRS. However, unlike in the anterior chamber, P815 tumors in the SRS did not continue to grow indefinitely (Wenkel, Chen, Ksander, & Streilein, 1999) . Between 12 and 16 days p.i. P815 tumors began to recede, and eventually the tumors were completely eliminated from the SRS in most eyes. While this result could be interpreted to mean that immune privilege in the SRS is only partial, the results of the studies described below have cast doubt on that interpretation.
Wenkel also investigated into the nature of the systemic immune response to the alloantigens expressed on P815 tumors growing in the SRS. He found that mice bearing these tumors acquired tumor-specific ACAID. That is, these mice failed to display P815-specific DH. Wenkel also showed that this outcome was not restricted to minor transplantation antigens expressed by tumor cells. In companion experiments, he demonstrated that subretinal injection of Ovalbumin (OVA) also impaired the capacity of recipient mice to acquire OVA-specific DH when immunized subsequently. In fact, spleen cells from mice that received a SRS injection of OVA were able to transfer impaired DH capacity when injected into na€ ı ıve BALB/c recipients.
Thus, the SRS displays two important features of immune privileged sites: it accommodates and in fact protects allogeneic tissue grafts from immune rejection, and it promotes the acquisition of systemic immune deviation to antigens placed in this site. These features should have the effect of promoting the survival of allogeneic grafts of neuronal retina and RPE implanted into this space.
Is retinal pigment epithelium an immune privileged tissue?
Given that the SRS is an immune privileged site, orthotopic transplants of RPE allografts to this site is an unsatisfactory manner in which to determine whether RPE--as a tissue--is immune privileged. To examine this point, we have taken advantage of the subcapsular sinus of the kidney--a site that was developed by transplantation immunologists in the early 1970s as a heterotopic site to evaluate immune rejection of a wide variety of solid tissue grafts (Reece-Smith, DuToit, McShane, & Morris, 1981) . Studies at that time indicated that the subcapsular sinus of the kidney is not immune privileged. It has a robust blood supply, is populated with numerous macrophages and dendritic cells of bone marrow origin, and it displays inflammation readily when an appropriate stimulus is applied. Recently, Bellgrau and his colleagues have used the subcapsular sinus as a conventional site in which to test the immune privileged status of testicular tissue (Bellgrau et al., 1995) . These workers demonstrated that allogeneic testis tissue, especially the Sertolli cells, survived without risk of immune rejection when placed beneath the kidney capsule of adult, normal, mice. Drawing on this model, Hori et al. similarly demonstrated that epithelium-deprived corneal allografts survive indefinitely when placed beneath the kidney capsule (Hori, Joyce, & Streilein, 2000) .
Using this approach, Wenkel obtained intact sheets of neonatal RPE from C57BL/6 donors and implanted these tissues beneath the capsule of C57BL/6 and BALB/c kidneys (Wenkel & Streilein, 2000) . In the case of the C57BL/6 recipients, pigmented retinal pigment epithelial sheets were readily visible when graft-bearing kidneys were harvested and examined histologically up to 8 weeks later. This indicates that the alien environment of the subcapsular sinus of the kidney is suitable to allow neonatal RPE to engraft and thrive. More important, Wenkel found that neonatal C57BL/6 RPE allografts survived equally well for at least 8 weeks beneath the kidney capsule in BALB/c recipients. By contrast, neonatal C57BL/6 conjunctiva allografts placed beneath the kidney capsule were destroyed within 2 weeks, showing vigorous inflammation at the graft site. No evidence of inflammation was present in or around the site of long-standing allogeneic RPE grafts. These results formally demonstrate that neonatal RPE is an immune privileged tissue. Whether it will turn out that adult RPE is similarly immune privileged remains to be determined. Moreover, it is important to know whether single cell suspensions of fresh or cultured RPE also displays properties of immune privileged tissues.
Is neural retina an immune privileged tissue?
For the same reasons described above for RPE, the immune privileged status of the neural retina cannot be judged on the basis of the fate of these grafts in the SRS--itself an immune privileged site. An alternative graft site must be used to examine this issue. With some trepidation, our laboratory has utilized the subcapsular sinus of the kidney to explore this question. In initial studies, Tat Fong Ng implanted intact segments of full thickness adult retina beneath the kidney capsule (Ng, Hori, & Streilein, 2001 ). Whether these grafts were obtained from syngeneic or allogeneic donors, they failed to survive in this alien environment. Both types of adult retinal grafts disintegrated within 24-h long before immunity could be implicated in the graft's destruction. At least for the moment, we are unable to say anything about whether adult neural retinal tissue is immune privileged.
We are, however, able to comment on the privileged status of NNR. Ng has found that implants of syngeneic intact NNR placed beneath the kidney capsule thrive! These heterotopic transplants proceeded through their developmental program by forming robust rosettes of photoreceptors, and the rosettes were surrounded by neural cells suggestive of amacrine and bipolar cells. Over a period of 12 days these implants even displayed a modest neuropil and generated neural cells that resemble ganglion cells. Grafts of this type have been observed through 20 days without any evidence of deterioration. Thus, NNR tissue when placed in the SRS is able to accommodate sufficiently well that it survives and carries out important elements in its developmental program.
When allogeneic NNR grafts were placed in the subcapsular sinus of the kidney, a similar development takes place: rosettes formed, other retinal cellular elements appeared, and a modest neuropil accrued. When examined at 12 days p.i., these grafts were devoid of cellular evidence of inflammation. Since allografts of non-neural tissue, such as skin or conjunctiva, placed beneath the kidney capsule were already rejected by immune effectors at 12 days, the survival without inflammation of NNR allografts at 12 days beneath the kidney capsule implies that this tissue possesses inherent immune privilege.
However, Ng's experiments indicate that this privileged status is not absolute. Between 12 and 20 days p.i., a brisk inflammation invaded allografts of NNR beneath the kidney capsule and at the end of this interval, all recognizable elements of the NNR implant were destroyed. The reasons why immune privilege is terminated in this manner have yet to be elucidated, but our suspicions include the fact that microglia--are normally present in NNR implants at the time of grafting, and microglia can be potent antigen presenting cells (Thanos, Moore, & Hon, 1996; Cash & Rott, 1994) . Nonetheless, we believe that NNR acts as a partially immune privileged tissue, and we are hopeful that in the future we can develop strategies to determine whether adult neural retina shares these properties.
Do cells of neuronal retina express transplantation antigens? And do these tissues as allografts sensitize their recipients?
For many year it was reported that the major transplantation antigens, class I and class II MHC-encoded molecules, are not expressed by neurons (Rao, Lund, Kunz, & Gill, 1989) . Recent findings from Shatz et al. (Huh et al., 2000) demonstrating class I MHC expression on certain neurons during development makes the preceding statement no longer uniformly true. However, it remains true that MHC molecules are not expressed on the vast majority of mature, adult neurons. Moreover, even exposing mature neurons to interferon-c typically fails to cause expression of MHC class I and II genes. However, this does not necessarily mean that neurons express NO transplantation antigens. It is entirely possible that minor histocompatibility antigens are expressed by neurons. However, in the absence of MHC class I expression, neurons lack the capacity to display peptides derived from minor H antigens. Upon death of neurons, minor H antigens can be released, and when these molecules are captured by antigen presenting cells, neuron-derived minor H antigens can then be detected by immune T lymphocytes.
But neurons are only a portion of neuronal retinal tissue. Glial cells, both Muller cells and astrocytes, constitutively express class I MHC molecules (Thanos et al., 1996) . Upon exposure to interferon-gamma, these glial cells not only increase class I MHC expression, but they begin to express class II MHC molecules. Thus, in the aggregate the cellular components of the neural retina that are derived from neurectoderm are capable of displaying transplantation antigens.
Microglia are also important constituents of neural retinal tissue. Even NNR tissue contains numerous microglia, and Ma and Streilein (1998) have demonstrated that these cells become activated when NNR tissue is implanted into the anterior chamber or within the SRS. Activated microglia display rounded cell bodies, shortened dendrites, they express the carbohydrate, a-Dgalactose, that is recognized by Griffonia simplicifolia lectin, and they display enhanced expression of class I molecules. More important, activated microglia in NNR grafts also express class II MHC molecules. Activation of microglia appears to be related to rosette formation, since activated microglia were routinely found within the centers of rosettes. As Banerjee and Lund (1992) had first observed, activated microglia within rosettes appear to be phagocytizing rod outer segments, and may be acting as RPE surrogates. Expression of class II molecules is especially prominent on microglia within rosettes of NNR allografts placed in ocular compartments. Thus, when NNR allografts express transplantation antigens, microglia appear to be the major purveyors of these important molecules.
Allogeneic NNR grafts placed intraocularly have an important consequence on the systemic immune system, indicating that their expression of transplantation antigens is relevant. NNR allografts placed in the anterior chamber or SRS induce donor-specific ACAID in their recipients within 12 days of implantation. Donor-specific ACAID proves to be transient, however, since it is eventually replaced by donor-specific DH. Similarly, allogeneic NNR grafts placed beneath the kidney capsule induce donor-specific DH. Thus, we interpret these results to mean that NNR grafts--primarily through their content of microglia--express transplantation antigens, and induce within their recipients either immune deviation or DH to donor alloantigens.
Do retinal pigment epithelial cells express transplantation antigens? And do these allografts sensitize their recipients?
Adult retinal pigment epithelial cells express class I MHC molecules constitutively, although the level is rather low compared to other epithelial cells in the body (Rezai, Semnani, Patel, Ernest, & van Seventer, 1997) . Under normal circumstances, RPE cells do not express class II MHC molecules, but when stimulated with IFNc, RPE up-regulate class II MHC genes. Although not formally tested, it is altogether likely that RPE also express minor histocompatibility antigens.
As mentioned previously, allogeneic neonatal RPE sheets implanted beneath the kidney capsule display immune privilege and survive without evidence of host inflammatory response for at least 12 weeks. To our surprise, recipients bearing these privileged grafts became sensitized to donor alloantigens. When tested in DH assays, recipients of subcapsular RPE allografts displayed intense ear swelling responses. This finding indicates that the systemic immune apparatus becomes aware of transplantation antigens on RPE grafts beneath the kidney capsule. In an analogous manner--but with a different immunologic outcome--neonatal RPE allografts placed in the anterior chamber or in the SRS induce donor-specific ACAID. Together these results indicate not only that RPE express transplantation antigens, but that these antigens are detected by T cells of the recipient. Why activation of donor-specific T cells under these circumstances does not lead to rejection of RPE grafts is a question of considerable interest.
11. Are allografts of retina vulnerable to rejection?
As already described, allografts of NNR placed beneath the kidney capsule induce donor-specific DH, and this reactivity coincides temporally with immune rejection of the graft. While formally answering the question in an immunologic sense, the vulnerability of retinal grafts placed within the eye is a different issue since, unlike the subcapsular sinus of the kidney, the eye itself is an immune privileged site. Almost a decade ago, Jiang reported that C57BL/6 NNR tissue implanted into the anterior chamber of BALB/c eyes eventually deteriorated, while BALB/c NNR tissue similarly implanted in BALB/c eyes did not (Jiang & Streilein, 1991) . This outcome indicated that immune factors are probably responsible for NNR graft rejection in the eye. Ng has now explored the fate of NNR grafts in the SRS and anterior chamber in great detail (Ng et al., 2001) . His studies indicate that NNR allografts gradually deteriorate in the eye by progressive loss of rosettes. The data suggest that individual rosettes collapse and are replaced by amorphous tissue fluid. Through time less and less of the graft is composed of rosettes and the total mass of the graft shrinks. A summary of results providing quantification of this analysis is displayed in Table 1 . What is particularly surprising is the utter lack of identifiable inflammatory cell infiltrates in these deteriorating grafts.
Possible insight into the mechanism of rejection can be inferred from studies conducted by Naili Ma (Ma & Streilein, 1998) . In syngeneic and allogeneic NNR grafts placed in the anterior chamber and SRS, microglia came to reside within the center of all rosettes. In allografts, microglia in these sites became particularly activated, with high levels of class II MHC antigens observed. Using histochemistry analysis of these grafts, Ma discovered that only donor-derived (not recipient) micro- Arbitrary scoring system reflecting portion of graft occupied by rosettes: 5þ, >85%; 3þ, between 50% and 70%; 1þ, <25%; 4þ, between 70% and 85%; 2þ, between 25% and 50%; 0þ, no graft identifiable.
glia were present within the grafts. Instead, recipient microglia congregated at the graft margin, but showed little evidence of penetration into the graft. However, recipient-derived leukocytes in small numbers were identified within allogeneic NNR allografts, and Ma demonstrated that virtually all of these cells were CD3 þ , indicating that they are T lymphocytes.
Taken together, these results, along with results described earlier in this paper, suggest the following scenario: microglia within allogeneic NNR grafts in the eye become highly activated and express high levels of class II MHC alloantigens. Perhaps some of these cells migrate out of the graft and through the eye into the general circulation where they lead to donor-specific DH. The T cells that mediate this type of reactivity then migrate through the blood back to the graft site. As individual effector cells they are able to penetrate into the graft and attack donor microglia directly. For some reason (perhaps the inherent immune privilege of the graft and the site), these T cells are not able to recruit non-specific host effectors (macrophages, neutrophils, etc.) that normally contribute to acute graft rejection in other tissues. Thus, rejection of NNR allografts can only occur slowly as individual T cells gradually seek, find, and destroy individual donor microglia. Since microglia may be playing a central neurobiologic role in maintenance of graft integrity (substituting for RPE), the neural elements of the graft may collapse when microglial support is withdrawn. According to this idea, death of neural elements of the graft is secondary, rather than primary.
Are allografts of RPE vulnerable to rejection?
Since our studies have revealed neonatal RPE tissue to be immune privileged, one might conclude that RPE grafts are not vulnerable to rejection. Studies from our laboratory conducted by Hartmut Wenkel and Parisa Zamiri shed light on this issue, as do reports from Kohen (Kohen, Enzmann, Faude, & Widermann, 1997) and from Zhang and Bok (1998) . RPE resemble many other cells within the eye by their constitutive expression of CD95 ligand. In the case of corneal endothelium and testicular Sertolli cells, constitutive CD95 ligand expression is an important component of their immune privileged status as tissues. Wenkel investigated this possibility with respect to RPE. He reported that neonatal RPE allografts prepared from donors genetically deficient in CD95 ligand expression were rejected when placed beneath the kidney capsule (Wenkel & Streilein, 2000) . Thus, if CD95 ligand expression is ablated on RPE, immune privilege is lost and as allografts the RPE can be rejected. But what about RPE grafts placed in the SRS?
Zhang and Bok reported indirect evidence supporting their claim that allogeneic retinal pigment epithelial cells, placed as single cell suspensions in the SRS of RCS rats, suffered chronic, rather than acute, rejection. Since they never implanted allogeneic RPE into the SRS of non-diseased eyes, their data cannot rule out the possibility that the gradual deterioration of the RPE transplants in RCS eyes is related to the pathology inherent in the recipient SRS. Kohen et al. injected single cell suspensions of allogeneic RPE that were treated with IFN-c (or not) into the SRS of rabbits and found that acute rejection was observed only with the IFN-c-treated cells. We wonder whether single cell suspensions of RPE might be less immune privileged than intact sheets of RPE. Experiments to test this possibility are underway.
Zamiri has taken a more direct approach to the question of vulnerability of RPE to immune rejection (Zamiri & Streilein, 2000) . She has immunized BALB/c mice to transplantation antigens of C57BL/6 mice. Lymphocytes removed from the immunized mice were readily able to kill C57BL/6 target cells (tumor cells) in vitro. In one set of experiments, Zamiri injected these specifically sensitized T cells into the SRS of normal C57BL/6 mouse eyes. Within 5 days the RPE directly at the site of injection underwent vacuolar changes and then disintegrated. However, lysis of surrounding RPE cells did NOT occur, even though the cytotoxic T cells possessed the inherent potential to continue to kill target cells until all had been consumed. The inability of the injected cells to systematically destroy the entire layer of RPE in the SRS strongly suggests that factors in the SRS, or RPE cells themselves, possess a native resistance to cytotoxic T cell lysis.
In another set of related experiments, Zamiri created C57BL/6 posterior eyecups from which the neural retina was removed, leaving behind an intact layer of RPE. She then layered BALB/c-anti-C57BL/6 T cells over the RPE monolayer and examined by confocal microscopy for evidence of RPE death. Whether the cultures were incubated for 4 or 18 h, no evidence of RPE lysis was observed. Even when RPE cells were incubated with high levels of IFN-c, they continued to resist cytotoxic T cell lysis. In some cultures, containing IFN-c-treated RPE that were incubated for 18 h with sensitized T cells, small evidence of individual RPE lysis was found. Posterior eye cups prepared from C57BL/6 donors deficient in CD95 ligand expression were no more vulnerable to T cell killing than RPE from normal eye cups.
Together these results indicate that immune privilege acts at multiple levels in RPE and that factors in addition to CD95 ligand help to create the privileged status. If these various protective factors can be overcome, then RPE may display vulnerability to immune rejection mechanisms.
Summary and conclusions
Neonatal neuronal allografts placed either within the anterior chamber or the SRS of mouse eyes display prolonged survival. When donor and recipient differ at major and minor histocompatibility loci, these grafts eventually undergo rejection, but by a mechanism that lacks the histologic hallmarks of inflammation. The pathogenesis of rejection in this circumstance is obscure, but microglia of graft origin may prove to have a central role to play both as initiators of recipient immunity, and as targets of immune attack.
Neonatal retinal pigment epithelial cells and neonatal neuronal retinal grafts express transplantation antigens. In the case of NNR grafts, the burden of transplantation antigen expression seems to be borne by microglia. When allografts of these tissues are placed beneath the kidney capsule (a non-immune privileged site), they instigate donor-specific DH, but when they are placed in the anterior chamber or SRS, the initial systemic immune response is deviant, i.e., devoid of DH. This propensity may auger well for the eventual ability of these grafts to be accepted.
